Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer by Marcus Moses, MS, Alex Niu, MD, Michael B. Lilly, MD, Andrew W. Hahn, MD, Roberto Nussenzveig, PhD, Elisa Ledet, PhD, Charlotte Manogue, MPH, Patrick Cotogno, MSPH, Brian Lewis, MD, MPH, Jodi Layton, MD, Neeraj Agarwal, MD, Oliver Sartor, MD, Pedro C. Barata, MD, MSc

Get full text